Docetaxel and S-1 treatment for patients with metastatic breast cancer
Phase 2
Completed
- Conditions
- Anthracycline resistant metastatic breast cancer
- Registration Number
- JPRN-jRCT1091220030
- Lead Sponsor
- Kobe Breast cancer Oncology Group (KBCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1.Histologically or cytologically proven as breast cancer
2.Metastatic or recurrent breast cancer
3.Four weeks after the last administration of endcrine therapy
4.One year after the last administration of Docetaxel
5.Two weeks after the radiation therapy
6.Performance Status:0?2
7.Age 20 to 74 year old
Exclusion Criteria
1.Suspected infection
2.Abundant of pleural effusion and ascites
3.Simultaneous or metachronous (within 5 years) double cancers , with the exception of intramucosal tumor curable with local therapy
4.Decetaxel resistant
5.Grade 2 edema
6.Interstitial pneumonia
7.Brain metastasis with clinical manifestation
8.HB antigen positive
9.HER 2 positive
10.Pregnant or lactating women or women of childbearing potential
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method